Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Cyanotech Corporation (CYAN) Stock Price
News articles about Cyanotech Corporation (NASDAQ:CYAN) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cyanotech Corporation earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.7607411353557 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- Macroeconomic and Microeconomic Carotenoids Market Analysis by 2016 – 2024 (mynewsdesk.com)
- Global astaxanthin market by source – plants, yeast & microbes, marine and petroleum made available by top research firm (whatech.com)
- Cyanotech Corporation (CYAN) Lowered to “Sell” at ValuEngine (americanbankingnews.com)
- Cyanotech Corporation’s (CYAN) CEO Gerry Cysewski on Q3 2017 Results – Earnings Call Transcript (seekingalpha.com)
Shares of Cyanotech Corporation (CYAN) traded down $0.15 during trading on Tuesday, reaching $4.20. 4,800 shares of the company’s stock traded hands, compared to its average volume of 5,565. The stock has a market capitalization of $24.12, a price-to-earnings ratio of 72.50 and a beta of 1.14. Cyanotech Corporation has a one year low of $3.25 and a one year high of $5.35. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.36 and a quick ratio of 0.72.
Cyanotech Corporation (NASDAQ:CYAN) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported $0.08 EPS for the quarter. The company had revenue of $8.06 million for the quarter. Cyanotech Corporation had a net margin of 1.11% and a return on equity of 2.06%.
Several equities analysts have commented on CYAN shares. ValuEngine lowered shares of Cyanotech Corporation from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. TheStreet upgraded shares of Cyanotech Corporation from a “d” rating to a “c-” rating in a research note on Monday, August 28th.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Cyanotech Corporation (CYAN) Stock Price” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/11/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-cyanotech-corporation-cyan-stock-price.html.
About Cyanotech Corporation
Cyanotech Corporation is engaged in the production of natural products derived from microalgae for the nutritional supplements market. The Company’s products include Hawaiian Spirulina Pacifica and Hawaiian BioAstin. Hawaiian Spirulina Pacifica is a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids.
Receive News & Ratings for Cyanotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyanotech Corporation and related companies with MarketBeat.com's FREE daily email newsletter.